- RoslinCT has entered into a strategic partnership with BlueRock Therapeutics to expand access to clinical-grade induced pluripotent stem cell (iPSC) lines for cell therapy developers.
- The partnership adds BlueRock’s clinical-grade cell lines to RoslinCT’s CDMO offering and enables development and manufacturing services from early-stage research through clinical and commercial supply.
RoslinCT has announced a strategic partnership with BlueRock Therapeutics to expand access to clinical-grade induced pluripotent stem cell (iPSC) lines for cell therapy developers. Under the agreement, RoslinCT will add BlueRock’s clinical-grade iPSC lines to its existing pluripotent cell therapy offering alongside its own cell lines and related development and manufacturing services. The companies said the collaboration is intended to support developers progressing pluripotent cell-based therapies from early development to clinical and commercial manufacturing.
As part of the partnership, RoslinCT will provide prospective customers with access to matched research-grade samples of BlueRock’s cell lines, while BlueRock will retain responsibility for commercial licensing. The companies have also completed the technical transfer of the cell lines to RoslinCT’s facilities, enabling the CDMO to provide services including cell banking, process and analytical development, and the contract manufacturing of drug products for clinical and commercial use.
“Pluripotent cell-based therapies are increasingly advancing in the clinic and show promise for cost-effective therapies for a broad range of conditions. By adding access to BlueRock’s clinical-grade lines alongside our own cell lines and development and manufacturing capabilities, we can provide customers with a more comprehensive pathway to support the development of advanced therapies from early-stage evaluation through to clinical and commercial supply.”
Peter Coleman, Chief Executive Officer of RoslinCT
According to the companies, BlueRock has invested in developing clinical-grade pluripotent stem cell capabilities to support its therapeutic programs and will make these cell lines available through RoslinCT. The collaboration is intended to provide cell therapy companies with additional resources to advance therapies toward clinical development.
RoslinCT said its capabilities span process and analytical development, cell banking, gene editing, differentiation, GMP manufacturing, and commercial supply across autologous, allogeneic, and pluripotent cell therapy platforms.
